Skip to main content

Table 3 Treatment modalities of patients with localized PG-DLBCL

From: Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution

Treatment

N

5-year RFS

P value

5-year OS

P value

Radical surgery

74

88.5 ± 4.4 %

0.004

87.7 ± 4.8 %

0.004

Alleviate surgery

27

69.5 ± 9.7 %

72.3 ± 9.7 %

Radical surgery and chemotherapy with Rituximab

44

93.8 ± 4.3 %

0.302

93.3 ± 4.6 %

0.333

Radical surgery and chemotherapy without Rituximab

21

88.2 ± 7.8 %

88.2 ± 7.8 %

Alleviate surgery and chemotherapy with Rituximab

16

92.9 ± 6.9 %

0.002

91.7 ± 8.0 %

0.001

Alleviate surgery and chemotherapy without Rituximab

8

58.3 ± 18.6 %

71.4 ± 17.1 %

  1. Abbreviations: PG-DLBCL primary gastrointestinal diffuse large B cell lymphoma, RFS relapse-free survival, OS overall survival